Early detection of bladder cancer in Yorkshire: feasibility assessments for implementing a targeted study in populations with high disease-specific mortality risk
Bladder cancer
Current intervention as of 15/07/2022: This study aims to assess the feasibility of urine self-testing as an early detection method for bladder cancer. The study will also collect data to help design a larger trial in the future. Three different populations are included in this study: Cohort 1: 2000 participants of the Yorkshire Lung Screening Trial (YLST) Cohort 2: 3000 male participants identified to live in a high-risk bladder cancer mortality region Cohort 3: 1000 NHS patients being investigated for bladder cancer in the 2 week wait (2WW) pathway. Identification Cohort 1 identification will integrate with Visit 2 of the YLST to identify participants. The YLST, based in Leeds, is an implementation study, primarily measuring participation rates of a community-based lung cancer screening programme. Patients eligible for YLST are registered with a GP in the Leeds CCG area. YLST participants identified to be at high risk of lung cancer are invited to attend a mobile lung health check which includes a CT scan of the lungs. Most participants are invited for a second scan 2 years after their first (Visit 2). On attending the YLST Visit 2 participants are asked for their consent for contact from other research teams. Personal data from those that give this consent will be securely transferred to KCL in order to invite them to take part in the study. A study invitation will not be sent to these participants for at least 2 months after their YLST visit so as not to overlap with trial or clinical follow-up. Identification of YORKSURe participants through the YLST will target smokers (who are at increased risk of bladder cancer as well as lung cancer) and test the acceptability of urine self-testing in a population already engaged with a screening programme/study. This may indicate whether embedding lung and bladder cancer screening programmes would be successful in the future national roll-out. Cohort 2 participants will be identified through a database search of 8-10 sele
Cohort 1: 1. Men and women 2. Aged 55 – 80 years 3. Participants already enrolled within the YLST 4. Registered with a GP within the Leeds CCG area 5. Consented to contact from other research teams at the second YLST Lung Health Check visit Cohort 2: 1. Men aged 65-79 years 2. Registered with a GP Practice identified as being in a region with a high bladder cancer mortality risk Cohort 3: 1. Men and women aged 65-79 years referred to a recruiting urological department under the 2WW pathway for the investigation of haematuria (to include cystoscopy and urinary tract ultrasound, ± CT urogram)
Current exclusion criteria as of 15/07/2022: Cohort 1: 1. Unable to/did not consent to contact from other research teams 2. Insufficient capacity to give consent to take part in the research as determined by the investigator/person taking consent for those that attend an Early Detection Clinic appointment. Cohort 2: 1. National Data Opt-outs 2. Ever diagnosis of bladder or kidney cancer 3. Diagnosis with any other cancer within the past 5 years (except non-malignant skin cancer) 4. Insufficient capacity to give consent to take part in the research, defined as the presence of the following conditions coded in GP records: 4.1. Dementia 4.2. Alzheimer’s disease 4.3. Parkinson’s disease or as determined by the investigator/person taking consent for those that attend an Early Detection Clinic appointment Cohort 3: 1. Unable to provide written informed consent 2. Insufficient capacity to give consent to take part in the research, defined as the presence of the following conditions in medical notes: 2.1. Dementia 2.2. Alzheimer’s disease 2.3. Parkinson’s disease or as determined by the investigator/person taking consent at the 2WW appointment 3. Evidence in patient medical record of historic dissent to use of data in research 4. Participant has opted out of data use via the National Data Opt Out Previous exclusion criteria: Cohort 1: 1. Unable to/did not consent to contact from other research teams 2. Insufficient capacity to give consent to take part in the research as determined by the investigator/person taking consent for those that attend an Early Detection Clinic appointment. Cohort 2: 1. National Data Opt-outs 2. Ever diagnosis of bladder or kidney cancer 3. Diagnosis with any other cancer within the past 5 years (except non-malignant skin cancer) 4. Insufficient capacity to give consent to take part in the research, defined as the presence of the following conditions coded in GP records: 4.1. Dementia 4.2. Alzheimer’s disease 4.3. Parkinson’s diseas